Hope Rugo
@hoperugo
Followers
11K
Following
5K
Media
551
Statuses
4K
#MASCC2025 Antonio Villa gives a very helpful talk about oral toxicities from targeted therapies. @OncoAlert see his recent paper on grading and management of oral irAE in JCO OP!
3
7
29
Beautiful lift off now on their way to the space station! @AstroPeggy with an international crew! @Axiom_Space.
LIFTOFF of Axiom-4 🚀.After 41 long years, an Indian astronaut is finally on his way to space! 🇮🇳
0
1
7
Axiom 4 lifts off! International collaboration a model for our times. @AstroPeggy go crew!.@Axiom_Space
0
0
0
Well said.
"You have a crappy job giving crappy news to people you don't know, I'm sorry you're spending your weekend doing this" 🥹. Have to admit, it's people like this that make our job not crappy, and there are worse ways to spend your time on a Saturday than helping people.
0
0
6
Amazing results - humans listened to the data in mice! Important to keep in mind that 40% had adj tamoxifen and essentially no adj CDKI. Will be interesting to see next results in later relapse and second line. #asco25.
#ASCO25. INAVO120: Inavo + palbo + fulvestrant in 1L PIK3CA-mutant HR+/HER2– aBC. OS ➡️ 34.0 vs 27.0 mo✅️.PFS ➡️ 17.2 vs 7.3 mo.TTC ➡️ 35.6 vs 12.6 mo. Hyperglycemia (any) ➡️ 63.4% vs 13.5%. Clear OS benefit & ~2y chemo delay—an important advance in endocrine-resistant HR+ aBC.
1
2
19
No big BC data but huge potential for triple negative disease at least. Excited for the future.
Power Pairing: PD-(L)1 and VEGF BsAbs Reshape the Oncology Landscape. Round-up from @ASCO 2025. Get the latest #ASCO25 updates as they happen: #LARVOL #BsAbs #CancerResearch #Oncology #OncologyInsights #CancerData #ClinicalTrials | @HHorinouchi |
1
1
4
RT @OncNewsCentral: Leadership churn at @OHSUKnight: Dr Thomas Sellers resigns, Dr Lisa Coussens steps in as interim—follows Dr Brian Druke….
0
1
0
Congratulations and well deserved!!.
👏👏👏.
0
0
1
Me too. Fabulous faculty and thrilled to moderate this group. And what a year!!.
I am much looking forward to this! See you in Chicago.@WinshipAtEmory.
0
0
0
RT @ASCOPres: Every year, @ConquerCancerFd funds the work of hundreds of researchers across the oncology community so we can continue makin….
0
15
0
RT @myESMO: #ESMOMembers vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Memb….
0
15
0
RT @n8pennell: Bispecific Antibodies in Non–Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration | American Society o….
0
43
0
RT @n8pennell: Artificial Intelligence in the Clinic: Creating Harmony or Just Adding Noise? | American Society of Clinical Oncology Educat….
0
26
0
Honored to be nominated for the ESMO nomination committee. Great candidates from around the world for the open positions - check them out on line!. And vote! @myESMO #ESMO.
📢It's #ESMO election time!. I am delighted to be nominated for ESMO Director of Education 😊. ALL the nominees are fantastic representing the global @myESMO community 🌍. 🙏for all the good wishes . Rules this year for social media so that's it from me! . Now please vote 🗳️
1
4
26
Very nice review article impactful for clinical practice. Advancing breast cancer treatment in the era of molecular diagnostics - The Breast. @TheBreastOnline @curijoey @JavierCortesMD
0
14
26
Wow. That is news I hadn’t seen yet. Lack of activity in wild type disease must be driving that change. Still too bad.
Arvinas lays off 33% of staff and discontinues two phase 3 trials of 1L vepdegestrant+CDK4/6i and 1L vepdegestrant+CDK4i (atirmociclib). Further development of the PROTAC will focus on the 2L setting.
0
1
3
RT @n8pennell: Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology | Amer….
0
10
0
Nicely done! Agree meeting is a favorite. For your list - not to miss a mini oral from I-SPY 2.2 by Kay Yeung evaluating VV-1 and cemiplimab as NAC in block A. Very interesting data! @ISPY2trial @UCSD see you soon #esmobreast25.
Only 2 weeks to #ESMOBreast25, one of my favorite conferences. Dozens of impactful abstracts to be presented, alongside great educational presentations to put the new data into context. Here’s a personal selection of 10 key presentations to follow during the conference. #bcsm
2
3
30